(Q57407566)

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Orchiectomy combined with cyproterone acetate or prednisone in the treatment of advanced prostatic carcinoma. A randomized clinical and endocrine study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. International Prostate Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate--an Australian multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Combination treatment versus LHRH alone in advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final anal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Pituitary adrenal and gonadal endocrine suppression for the primary treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Anti-androgens in treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Overview analysis issues using combined androgen deprivation overview analysis as an example.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902163-2

7 January 2021